Because the feasibility of circulating biomarkers can be affected by renal dysfunction, with AKR1B10 being expressed in renal tissue [22], we intended to assess the performance of plasma AKR1B10 across CKD stages in the prediction of hepatic steatosis and advanced fibrosis, which were estimated and categorized by using the eGFR, hepatic steatosis index (HSI), and FIB-4, respectively. This evidence concerns the gene AKR1B10 and fatty liver disease.